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Human papillomavirus infection is associated with the development of malignant and benign neoplasms.
Approximately 40 viral types can infect the anogenital mucosa and are categorized into high- and low-risk
oncogenic human papillomavirus, depending on their association with the development of cervical carcinoma.
High-risk human papillomavirus 16 and 18 are detected in 55% and 15% of all invasive cervical squamous cell
carcinomas worldwide, respectively. Low-risk human papillomavirus 6 and 11 are responsible for 90% of genital
warts and are also associated with the development of recurrent respiratory papillomatosis. Human papillo-
mavirus preferentially infects mitotic active cells of the basal layer from both mucosal and cutaneous epithelium
through microabrasions. The viral life cycle synchronizes with the epithelial differentiation program, which may
be due, in part, to the binding of differentially expressed cellular transcription factors to the long control region
throughout the various epithelial layers. This review aimed to summarize the current knowledge regarding the
mechanisms by which viral gene expression is regulated and the influence of human papillomavirus hetero-
geneity upon this phenomenon. A better understanding of the regulatory mechanisms may elucidate the
particularities of human papillomavirus-associated pathogenesis and may provide new tools for antiviral therapy.
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’ INTRODUCTION
Human papillomavirus (HPV) infection is strongly asso-
ciated with the development of several malignant and benign
neoplasms. Over 200 different HPV genotypes have been
isolated, thoroughly sequenced and numbered in order of their
discovery, among which approximately 40 types can infect the
anogenital mucosa (1). These types are also categorized into
high- and low-risk oncogenic HPVs based on their association
with the development of cervical carcinoma. HPVs 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 are classified by the
International Agency for Research on Cancer (IARC) as carcino-
genic in humans (type I carcinogens), while HPVs 6, 11, 40, 42,
43, 44 and 54 are grouped as low-risk oncogenic viruses (2).
The association between HPV infection and the develop-
ment of cervical cancer was first reported in the early 1970s (3).
Although most infections are asymptomatic and spontaneously
eliminated, persistent infections by high-risk HPVs are respon-
sible for the development of most, if not all, cervical cancers
worldwide (4). HPVs 16 and 18 account for approximately 55%
and 15% of all invasive cervical squamous cell carcinoma (SCC)
worldwide, respectively (5). Furthermore, approximately 85%
of anal canal tumors, 50% of vulvar and penile tumors and 70%
of vaginal tumors can be attributed to HPV infection, in addi-
tion to 10% to 90% of oropharynx cancers. It is noteworthy that
HPV-16 is detected in almost all cancers of these extracervical
anatomical sites that are associated with HPV infection (6,7).
On the other hand, low-risk HPVs 6 and 11 are responsible
for over 90% of genital warts (GWs) in both genders and are
also associated with the development of recurrent respira-
tory papillomatosis (RRP), which is characterized by the
repeated formation of benign papillomas in the upper respi-
ratory tract (8,9). Nevertheless, although classified as low-
risk, HPV-6 has been identified in several malignancies, including
carcinomas of the vagina (10), vulva (11,12), penis (13),
tongue (14), cervix (15,16), and tonsils (17).
HPVs are nonenveloped viruses with a circular, double-
stranded genome that comprises approximately 8000 base
pairs (bp) (18). The viral genome is physically divided into
3 regions: the early (E) and late (L) regions and the long con-
trol region (LCR). E1 and E2 proteins play a role in regulating
viral DNA transcription and replication (19), whereas E4, E5,
E6, and E7 proteins are involved in cell cycle deregulation,
immune evasion and recruitment of replication host factors (20).
L1 and L2 late proteins comprise the major and secondary
capsid proteins, respectively.
HPVs infect the stratified squamous epithelia, both mucosal
and cutaneous, and preferentially target mitotically active cells
of the basal layer through microtraumas. In basal epithelia cells,
HPVs are established as episomes within the nuclei, and expres-
sion of early proteins that are necessary for DNA replication
occurs (20). As basal cells undergo differentiation, the expres-
sion pattern of HPVs is modified. Finally, in more differ-
entiated cells, late gene expression occurs, and new virions
are released (21). The switch between HPV promoters activa-
tion in the cells of supra basal layers suggests that synchro-
nization of the viral life cycle to the epithelial differentiationDOI: 10.6061/clinics/2018/e486s
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program is due to, at least in part, the binding of a repertoire of
differentially expressed cellular transcription factors (TFs) to the
LCR throughout the various layers of the epithelium.
This review summarizes the current knowledge regard-
ing the mechanisms of viral gene expression regulation at the
transcription level and the influence of HPV heterogeneity
upon this phenomenon. Advances in the knowledge of the
regulatory networks may shed light on the particularities of
HPV-associated pathogenesis that are relevant for disease
establishment and may provide new tools for antiviral therapy.
The long control region
The LCR is a noncoding region between the L1 and E6
genes that comprises approximately 10% of the viral genome
and is physically divided into three distinct segments: the
50 segment, the central segment and the 30 segment.
Most mucosal HPVs present four E2 binding sites (E2bs)
distributed along all the three LCR regions. The 50 segment
contains the first E2bs, in addition to the transcription termi-
nation and polyadenylation sites for late transcripts. The central
segment of the LCR is flanked by two E2bs and has been
shown to function as an epithelial-specific transcriptional
enhancer (22-24). This segment encloses several motifs that
are important either to stimulate or to suppress viral trans-
criptional activity. These motifs include binding sites to AP1,
NF1, TEF1, OCT1, YY1, BRN-3a, NF-IL6, KRF-1, NF-kB, FOXA1,
and GATA3, aming several others (25-28). Thus, the activation/
repression of HPV early promoters involves synergism between
these proteins, which vary in affinity for the different cis-elements
within the LCR of the different HPV types and variants. Finally,
the 30 segment of the LCR contains two E2bs in addition to an
E1 binding site (E1bs) overlapping the origin of replication.
P97 and P105 are the main early promoters of HPVs 16 and
18, respectively, and are also the most well studied. For both
high-risk HPVs, transcripts initiated in E6 are differentially
edited, codifying all early genes (29) (Figure 1). Additionally,
for both viral types a part of the E6 mRNA is spliced out for
efficient translation of E7 (30).
In contrast, in low-risk HPVs 6 and 11, two early pro-
moters have been identified, P90 and P270, that enable
the individual regulation of E6 and E7 genes, respectively,
although the regulation of both promoters is controlled by
cis-elements within the LCR (30-35). It is noteworthy the
Figure 1 - Schematic representation of the LCR and E6 and E7 genes from high- and low-risk HPVs, represented by HPV-16 and HPV-6,
respectively. Four E2 binding sites (E2bs) are conserved among mucosal HPVs, with E2bs#1 and E2bs#2 dividing the LCR in three distinct
segments: the 5’ segment, the central segment and the 3’ segment. The 5’ segment contains the late transcription termination signal,
denominated ‘late pA’, the central segment functions as an epithelial-specific enhancer, and the 3’ segment encloses the ori region.
Early promoters are also indicated: HPV-16 (P97) and HPV-6 (P90, P270, P680).
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presence of a third early promoter in HPVs 6 and 11,
P680, that encodes the fusion protein E14E4 (36). It has been
reported that P90, P270 and P680 are differentially regulated,
indicating that the independent regulation of early proteins
is important to the viral life cycle (32,34,37-39). For example,
the binding of E2 to the most distal E2bs stimulates P270,
whereas E2 binding to both proximal sites inhibits the P90 E6
promoter (38). Furthermore, the P680 promoter was shown
to be used in a differentiation-specific manner both in vitro
and in vivo. Interestingly, whereas E7 mRNA was the most
abundant transcript in a cervical carcinoma sample, in a benign
genital wart, E14E4 transcripts were the most prevalent (15).
Transcriptional regulation of HPVs
Transcription is the first step of gene expression control,
followed by regulation of mRNA processing and other post-
transcriptional events. Transcriptional regulation not only
restricts the expression of early and late genes to when they
are needed but also limits the range of cell types that HPVs
are able to infect, avoids the premature expression of immuno-
genic viral proteins, and modulates virus biology in response
to hormones and growth factors (40-42). HPV transcription
is mostly controlled by the E2 viral protein in addition to
host cells TFs that bind to specific sequences within the LCR
which vary substantially among different viral types and
variants (43). HPV gene expression control also involves epi-
genetic changes, such as nucleosome remodeling and DNA
methylation (44).
Approximately 90 bp downstream of the E1 binding site is
where the transcription start site is located. A segment of
approximately 45 bp within these 90 bp contains a SP1 bind-
ing site overlapping the E2bs#3 and a TATA box overlapping
E2bs#4. The overlap of both E2bs with these cis-elements
occurs in such a way that occupancy by E2 proteins displaces
TFIID and the SP1 factor (45-49). In turn, the binding of SP1
and TFIID to the LCR sterically inhibits E2 binding, activat-
ing early promoters (46,49). In all mucosal HPVs, the spacing
of the SP1, TATA, and E2 binding sites at E6/E7 promoters
are conserved (28).
E2 is the most important viral transcriptional regulator in
HPV early expression and therefore has a high impact on E6
and E7 protein levels (25,50). In preneoplastic and malignant
neoplastic lesions, the viral DNA often integrates into the
cell genome (51), and integration seems to occur mostly at
random (52). However, viral integration usually results in
interruption of the E2 gene, abolishing E2-negative transcrip-
tional regulation and resulting in constitutive expression
of E6 and E7 proteins (25).
In addition to binding directly to its specific sequence,
E2 also influences viral transcription by recruiting cellular
factors to the viral genome. One of the best-characterized
host interactors of E2 is the bromodomain-containing protein 4
(Brd4), a transcription cofactor and chromatin regulator (53).
Both E2-mediated activation and repression of the early pro-
moter require interaction with Brd4 (54,55). A recent study
revealed that a phosphorylated region of Brd4 interacts
selectively with high-risk E2 proteins. The study showed that
the blockage of phospho-Brd4 activity alleviates E2-mediated
inhibition of HPV-18 promoter activity (56). Another study
demonstrated that Brd4 is capable of directly activating
HPV-18 transcription during early stages of infection in an
E2-independent manner, indicating that Brd4 plays a central
role in the dynamics of viral expression (57).
Another important virally expressed transcriptional reg-
ulator is the E84E2 protein, which is a product of splicing (58).
It was demonstrated that E84E2 proteins in HPVs 16, 18, and
31 are potent repressors of viral transcription, and the con-
served E8 component of E84E2 is capable of recruiting cellular
corepressors to inhibit transcription of the viral major early
promoter in such a way that is more efficient than the recruit-
ment by the E2 component (59-61). Host cell NCoR/SMRT
complexes have been reported to act as corepressors of E84E2
proteins in HPVs 1, 8, 16 and 31 (62). This complex encloses
GPS2, HDAC3, NCoR, SMRT and TBl1 and TBLR1 proteins
and is typically involved in transcriptional repression of
cellular genes.
Concerning cellular TFs that bind directly to the LCR,
there is a large list of well-characterized regulators (including
YY1, AP1, NF1, OCT1, SP1, and CDP), many of which con-
servatively bind to the central segment of the LCR of several
HPV types that infect the mucosa. These regulators have been
demonstrated to be relevant not only to HPV epitheliotrop-
ism but also to host cell differentiation-dependent regulation
of viral infection (25). It was recently reported that the cel-
lular CCCTC-binding factor (CTCF) has a conserved binding
site within the E2 open reading frame of high-risk HPVs, in
addition to a cluster of cis-elements in the late gene region of
the genomes of HPVs 16, 18, 31, 11, and 6. CTCF is recruited
during epithelial differentiation to regulate both the transcrip-
tion of E6 and E7 and transcript processing (63).
García-Vallvé and col. (2006) performed an in silico analysis
to search for putative cis-elements within the LCR of 61 papillo-
mavirus (PVs) types infecting 20 different hosts (43). Overall
this study indicated that the number and nature of TF binding
sites within the LCR can be much broader than described to
date, some of which are predicted to be present in most PVs,
whereas others cis-elements seems to be restricted to specific
PVs. Curiously, in this study, YY1 putative binding sites in the
LCR of HPVs 18 and 6 were not found, although the impact of
this TF upon the transcriptional activity of both viral types was
already demonstrated (64,65). It is noteworthy, however, that
the identification of a putative cis-element alone does not
implicate that this nucleotide sequence will always be bound
by its cognate TF. For instance, many cis-elements within the
various LCRs are juxtaposed or even overlapped with others.
We must also take into consideration the existence of degen-
erate and/or low affinity sites that could increase the number
of probable binding sites for a given protein. Furthermore,
some TF binding sites are very similar, such as the recognition
sequences for TEF-1, TEF-2 and YY1, and these sites may be
differently occupied depending on the availability of each of
these proteins (28).
Additionally, the HPV LCR embraces hormone-responsive
elements, including glucocorticoid response element (GREs)
and progesterone responsive elements (PREs). Complexes
formed by steroid hormones and receptor proteins inter-
act with these specific regulatory sequences and either
upregulate or downregulate the transcription of viral early
genes (66,67). The administration of exogenous estrogen
induces HPV-18 LCR activity in both squamous and glan-
dular cells of the cervix and vagina, leading to an increased
E6/E7 expression and to a higher susceptibility of neo-
plastic transformation (68). Likewise, a study regarding
smoking-related effects upon the LCR activity revealed
that tobacco smoke was able to activate the HPV-16 P97
promoter in a dose-dependent manner in tumor lung
cells. However, in nontumor lung cells, the same effect
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depended on the ectopic expression of HPV-16 E6 and E7
oncogenes (69).
Chromatin remodeling also plays a pivotal role in regulat-
ing HPV transcription. The HPV-16 genome contains nucleo-
somes in specific positions, one at the center of the viral
enhancer and another overlapping the replication origin and
the E6 promoter (44). Both nucleosomes repress the activity
of the early promoter, which is released by the addition of
SP1 and AP1 proteins (70). The influence of nucleosomes
upon viral early and late transcription events was also
reported in HPV-31: nucleosomes at both promoter regions
were activated through histone modifications during differ-
entiation (71).
In addition to the remodeling of nucleosomes, DNA
methylation also participates in the epigenetic regulation of
HPV gene expression. Host cell methyltransferases methy-
late HPV DNA, and viral DNA methylation profiles have
been related to important features of the viral life cycle (72).
Among these features, several studies have focused on the
analysis of E2bs methylation, and taken together, the data
reveal that differential methylation of the different E2bs has
an impact on the activation of viral E6 and E7 expression in
cervical lesions (73-75). Additionally, analysis of the methy-
lation status of CpG dinucleotides within TF binding sites in
the LCR of HPV-16 indicated that these epigenetic alterations
are linked to squamous epithelial differentiation (76).
While most studies regarding HPV transcriptional control
rely on early promoter activity, little is known about the
mechanisms regulating late promoters. The levels of a variety
of cellular TFs, including c-MYB, NF1, PAX5, NFAT, STAT5,
C/EBPb, among others, increase upon epithelial differentia-
tion; however, the functional relevance and how these various
factors contribute to transcription regulation remains unclear
(77,78). Recent findings indicate that transcript elongation is
also a critical step for viral late gene upregulation. It was
demonstrated that cyclin dependent kinase 9 (CDK9), CDK8
and Brd4 are recruited to activate the HPV-16 late promoter
under differentiation conditions and to assist Pol II complex
activity until transcription is accomplished (79). The viral
oncoprotein E7 might also activate the HPV-16 late promoter,
indicating that the virus, per se, also plays an active role in
regulating its own expression (80).
The study of HPV regulatory elements progressed rapidly
for approximately 15 years, beginning in the early 1980s, but
interest declined dramatically, which was possibly associated
with limitations of the available methodologies. However,
the understanding of HPV transcriptional regulation is far
from achieving maturity. In the last decade the development
of array technologies made possible the identification of
several additional TFs that impact HPV transcriptional acti-
vity. Competition assays using an array comprising 345 con-
sensus binding sites for different TFs identified factors that
specifically bind to the HPV-16 LCR in differentiated and
undifferentiated cells (77). It is noteworthy that the methodol-
ogy used was able to confirm several TFs already described to
influence the expression of HPVs, although most of the asso-
ciations reported were still unpublished.
In our laboratory a powerful approach was used to analyze
the effect of 704 TFs upon the transcriptional activity of
HPVs 16 and 18 using a large-scale transfection assay (26).
Twenty-eight TFs that stimulated and 36 that repressed
the LCR were identified, most of which had not yet been
described. Although many of the TFs appear to act by
indirect mechanisms, binding sites on the viral LCR for a
subset of these modulators were identified. Among these,
FOXA1 had the greatest effect upon HPV-16 and HPV-18
transcriptional activities, and this was a direct effect, as we
were able to show in vivo binding of FOXA1 to the LCR in
both viral types. Moreover, the differential expression pat-
terns of FOXA1 indicate that this protein may be important
to HPV-associated carcinogenesis: we observed that FOXA1
is expressed at higher levels in immortalized and HPV-
transformed cell lines than it is in normal cells (26), and
FOXA1 was further shown to be strongly expressed in basal
epithelial cells, preinvasive lesions, and cervical and head
and neck carcinomas (81). Sex determining region Y (SRY)-
box 2 (SOX2) has also been recently proposed as a trans-
criptional repressor of the HPV-16 LCR; SOX2 binds to three
putative binding sites identified in the enhancer sequence
of the LCR through direct interactions and leads to the
inhibition of E6 and E7 expression (82).
Impact of HPV nucleotide heterogeneity upon LCR
transcriptional activity
HPV taxonomy is based on the variability of the L1 gene
sequence, and viral genomes are classified as new types when
these have less than 90% of identity with any other type.
Additionally, genome heterogeneity of 1.0-10.0% and 0.5%-
1.0% define HPV variant lineages and sublineages, respec-
tively (83). HPV DNA variability studies have been used as
an important tool for the analysis of viral evolution. Addi-
tionally, it has been observed that specific HPV variants are
differentially associated with disease outcome. Since HPV
variants show approximately 5% of divergence within the
LCR, the impact of HPV nucleotide heterogeneity upon trans-
criptional activity has been analyzed since nucleotide diver-
gence could influence TF affinity for their recognition sites, thus
influencing E6/E7 levels and consequently the carcinogenesis
induced by these viruses. In fact, we reported that the HPV-18
P105 promoter is 12 times more transcriptionally active than
the HPV-16 P97 promoter (84). These results corroborate pre-
vious observations showing that although HPV-18 is 10 times
more efficient than HPV-16 in the transformation of human
keratinocytes, E6/E7 proteins of both viral types immortalizes
these cells with similar efficiency when expressed from a
heterologous promoter (85).
Since the early 90s it is know that nucleotide alterations
within the LCR among variants of HPV-16 overlap cis-
elements (86). Next, it was reported that whereas variants from
the A1-A3 sublineages have similar transcriptional activity, vari-
ants from the D sublineage attain higher activity, which may sup-
port augmented E6 and E7 levels and finally confer enhanced
oncogenic potential to specific variants (87). These observations
are in line with epidemiological data that indicate that HPV-16
variants from the D lineage are associated with an increased
risk of HPV persistence and cervical disease development
(88-95). Differences in transcriptional activity were attributed to
the E6-proximal end of the LCR, even though it was not pos-
sible to implicate the observed differences to a single nucleotide
alteration (96). It is also important to note that TF recognition
sequences could be created or abolished between HPV variants
due to nucleotide changes in the LCR. The expression of viral
E2 and E1 replicating proteins has also been influenced by the
heterogeneity in the LCR sequence inherent of HPV-16 variants,
which has affected the viral replication efficiency as well (97).
BRN3, a long-known cellular transcription factor, binds
directly to a specific motif of the HPV LCR, strongly
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stimulating its activity (98,99). BRN3 and nicotine from smok-
ing were shown to have a synergistic effect upon the LCR in
a variant-specific manner (100). The BRN3/nicotine response
increases the transcription HPV-16 E6/E7 genes and was
shown to be related to higher grades of cervical intraepithe-
lial neoplasia and cancer.
Although it was observed that the LCR sequence of HPVs 18
and 58 is more conserved than the LCR sequence of HPV-16,
there are significant differences in the early promoter activity
among molecular variants of both viral types (84,101). For
instance, we observed that Asian-Amerindian variants achieved
higher transcriptional activity than variants from the European
branch (84) (Figure 2A).
Genome variability of low-risk HPVs 6 and 11 has also
been evaluated, and molecular variants of both viral types
were phylogenetic grouped (102-104). It was reported that a
variant from the HPV-6 B1 sublineage is ten times more
transcriptionally active than a B3 variant is (105) (Figure 2B).
Since a significant association between variants of the B1
sublineage and the development of GWs was recently described,
it is possible to hypothesize that the increased transcriptional
efficiency could impact the increased expression of viral E1
and E2, which can confer B1 variants to have an increased
replication potential (106). Moreover, the results support a
crucial role of the ELF1 protein in the lower transcriptional
activity observed for the B3 variant (105). A correlation between
the transcriptional activity of specific HPV-11 variants and the
clinical aggressiveness of RRP has also been reported (107).
Additionally, it was reported that duplication in the early viral
promoter sequence of HPV-11 was associated with a higher
degree of disease severity (108).
A broader comprehension of HPV mRNA expression and
its regulation could lead to the development of novel diag-
nostic approaches and reveal strategic cellular targets for
the development of innovative antiviral therapies (25). Even
though inhibition of transcriptional regulatory factors could
be harmful to normal cells once it is required for host cell
homeostasis, these proteins could be inhibited using com-
pounds targeting specific LCR sequences, thus affecting viral
life cycle. Therefore, a molecule that could specifically bind
to cis-responsive elements indispensable for E6 and E7 trans-
cription of different viral types and variants could interfere
with the transformation process that is dependent on the
constitutive expression of both oncoproteins.
A recent approach based on TF research relied on the
identification of molecular signatures associated with HPV
positivity and the prognosis of head and neck cancers out-
come. In this context, differential expression of key tran-
scription factors, such as AP1, activator of transcription 3
(STAT3) and NF-kB, was reported between HPV-positive and
HPV-negative cancers (109-111). More specifically, in HPV-
positive squamous cell carcinomas of the oral cavity, higher
levels of AP1 and NF-kB in addition to a lack of STAT3 was
observed, and this pattern was suggested to be useful for
discriminating tumors with a better prognosis (110). There-
fore, the study of TF expression patterns may also provide
useful prognostic biomarkers as well as novel insights to the
molecular aspects of HPV-driven carcinogenesis.
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